These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21544977)

  • 1. [Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections].
    Płusa T
    Pol Merkur Lekarski; 2011 Feb; 30(176):91-6. PubMed ID: 21544977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R; Lode H; Graninger W; Milkovich G
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levofloxacin in the treatment of community-acquired pneumonia.
    Noreddin AM; Elkhatib WF
    Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin for the treatment of community-acquired pneumonia.
    Lynch JP; File TM; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):725-42. PubMed ID: 17140350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levofloxacin, a second-generation fluoroquinolone.
    North DS; Fish DN; Redington JJ
    Pharmacotherapy; 1998; 18(5):915-35. PubMed ID: 9758306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
    Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y
    Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Sollet JP
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S113-4. PubMed ID: 16904296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
    Grossman RF; Rotschafer JC; Tan JS
    Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin for the treatment of respiratory tract infections.
    Torres A; Liapikou A
    Expert Opin Pharmacother; 2012 Jun; 13(8):1203-12. PubMed ID: 22594848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.
    Davis R; Bryson HM
    Drugs; 1994 Apr; 47(4):677-700. PubMed ID: 7516863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
    Hoepelman I
    Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levofloxacin: an updated review of its use in the treatment of bacterial infections.
    Hurst M; Lamb HM; Scott LJ; Figgitt DP
    Drugs; 2002; 62(14):2127-67. PubMed ID: 12269858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue and serum levofloxacin concentrations in diabetic foot infection patients.
    Oberdorfer K; Swoboda S; Hamann A; Baertsch U; Kusterer K; Born B; Hoppe-Tichy T; Geiss HK; von Baum H
    J Antimicrob Chemother; 2004 Oct; 54(4):836-9. PubMed ID: 15375105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights in the treatment by levofloxacin.
    File TM
    Chemotherapy; 2004; 50 Suppl 1():22-8. PubMed ID: 15319551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of oral fluoroquinolones in patients with respiratory diseases].
    Ishida T
    Kekkaku; 2003 Oct; 78(10):653-9. PubMed ID: 14621574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolones in ambulatory ENT and respiratory tract infections: rarely appropriate.
    Prescrire Int; 2003 Feb; 12(63):26-7. PubMed ID: 12602405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxifloxacin: new preparation. A me-too with more cardiac risks.
    Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.